GPR119 receptor agonists on Methods to increase bone mass and to treat osteoporosis and other conditions characterized by Low bone mass and Combined Therapy related to these agonists

摘要

The current situation involves the use of gpr119 receptor agonists to treat or prevent low-quality bone diseases such as osteoporosis, and to increase personal osteoporosis. The current situation is also related to the use of gpr119 receptor agonists in combination with a dipdil-peptidasa IV (DPP-IV) inhibitor to treat or prevent low-quality osteoporosis and other low-quality osteoporosis, as well as the increase of one person's osteoporosis. The combination of gpr119 receptor enhancer and DPP-IV inhibitor can promote bone formation in human body.